Testosterone Therapy in Men: Who It’s For—and What It Might Cost

What the science says

Testosterone replacement therapy (TRT) is an established treatment for men with unequivocal hypogonadism—that is, persistently low testosterone due to defined disease of the hypothalamus, pituitary, or testes, plus compatible symptoms.[1][11][13] In this group, expert consensus views TRT as standard care rather than an optional “performance booster.”[1][11]

The controversy lies with age‑related or “functional” hypogonadism—men, usually middle‑aged or older, whose testosterone is modestly low and whose symptoms overlap with normal aging, obesity, and chronic disease.[1][8][10][14] For these men, large, long‑term trials are still lacking. Short‑ to medium‑term studies suggest modest benefits on sexual function, body composition, bone density, and mood, but durable effects on hard outcomes—fracture, disability, cardiovascular events, or mortality—remain unproven.[1][7][10][12][14]

Key evidence threads:

• Indications

  • Guidelines and major reviews agree that TRT should be considered only when both of the following are present:
    • Repeatedly low serum testosterone on morning samples, measured with reliable assays.[1][8][10][11][13]
    • Symptoms or signs consistent with androgen deficiency (reduced libido, low energy, loss of body hair, reduced spontaneous erections, low bone density, etc.).[1][8][11][13]
  • In men with clear structural or genetic causes (pituitary disease, testicular damage, congenital hypogonadism), evidence supports TRT for symptom relief, sexual function, bone density, and body composition.[1][11][13]

• Symptom relief and function

  • Across randomized trials in older men with low T, TRT shows consistent improvements in libido and sexual activity, with more modest or inconsistent effects on erectile function.[1][8][10][13]
  • Some trials report small gains in mood, vitality, and physical function, but the clinical significance is debated.[1][10][12][14]

• Metabolic and body composition effects

  • TRT generally increases lean body mass and reduces fat mass, especially visceral fat, although the change in strength or functional performance is modest.[2][6][8][13]
  • Short‑term trials show modest improvements in insulin resistance and some cardiometabolic markers, but it is unknown whether this translates into fewer diabetes or cardiovascular events.[1][6][7][10]

• Bone and fracture

  • TRT increases bone mineral density, particularly in the spine and hip, in hypogonadal men.[2][8][11][13]
  • Evidence that it prevents fractures is still limited; fracture reduction has not been robustly demonstrated in long‑term trials.[1][7][10]

• Cardiovascular risk

  • Early observational reports raised alarms about increased heart attacks and strokes in men on TRT, but subsequent analyses and randomized data have been mixed.[7][12][14]
  • Contemporary reviews conclude that high‑quality evidence for either harm or benefit is insufficient, with risk likely depending on baseline cardiovascular status, age, and dosing.[7][12][14][15]

• Prostate and other safety concerns

  • TRT is contraindicated in men with known or suspected prostate or breast cancer.[11][13]
  • Therapy can increase PSA and prostate volume; current data do not show a clear increase in prostate cancer incidence, but trials are too short to be definitive.[1][8][11][13][14]
  • Other frequent issues include erythrocytosis (high hematocrit), potential worsening of obstructive sleep apnea, peripheral edema, and suppression of sperm production.[2][8][11][12][15]

Broadly, the science supports TRT as established therapy for classic hypogonadism. For age‑related low T, the evidence is early‑to‑intermediate: enough to justify cautious, monitored trials in selected men, but not to endorse testosterone as an anti‑aging or longevity drug.[1][7][10][14]

How it works

Testosterone is produced mainly by the testes under the control of the hypothalamic‑pituitary‑testicular (HPT) axis. The hypothalamus releases GnRH, prompting the pituitary to secrete LH, which stimulates Leydig cells in the testes to produce testosterone. Rising testosterone feeds back to the hypothalamus and pituitary, maintaining a tight hormonal loop.[1][11][13]

When this axis is damaged or suppressed, testosterone levels fall and downstream androgen‑dependent tissues are affected.

What TRT is trying to restore

Classical hypogonadism reflects a clear disruption in this axis:

• Primary testicular failure (e.g., Klinefelter syndrome, chemotherapy or radiation damage, orchitis, trauma) leads to low testosterone with high LH/FSH.[1][11][13]
• Secondary hypogonadism (pituitary tumors, infiltrative disease, congenital GnRH deficiency, severe hyperprolactinemia) produces low testosterone with low or inappropriately normal LH/FSH.[1][11][13]

In both, the goal of TRT is relatively straightforward: replace the missing hormone to restore androgen‑dependent physiology—sexual function, muscle and bone maintenance, erythropoiesis, and aspects of mood and cognition.[1][11][13]

Functional or age‑related hypogonadism

In functional hypogonadism, the HPT axis is intact but inhibited by factors like obesity, chronic systemic illness, medications (e.g., opioids, glucocorticoids), or sleep disorders.[1][6][10][14]

• Visceral fat and systemic inflammation can lower GnRH and LH, reducing testosterone, while low testosterone in turn promotes further fat accumulation—forming a bi‑directional loop tied into metabolic syndrome.[6][10]
• Lifestyle interventions, weight loss, optimization of comorbidities, and removal of offending drugs can raise endogenous testosterone without exogenous hormones in some men.[6][10]

In this context, TRT is no longer just replacement; it effectively overrides adaptive or disease‑related down‑regulation of the axis. That distinction underlies much of the current debate.[1][10][14]

Downstream effects of TRT

Once administered as injections, gels, patches, or other formulations, exogenous testosterone:

• Increases androgen receptor signaling in muscle, bone, brain, and other tissues, promoting protein synthesis, larger muscle cross‑sectional area, and higher bone formation.[2][8][11][13]
• Suppresses pituitary LH and FSH, which in turn suppresses testicular testosterone and sperm production—important for fertility considerations.[11][15]
• Stimulates erythropoiesis in bone marrow, increasing hemoglobin and hematocrit. In excess, this leads to erythrocytosis, raising the risk of blood viscosity‑related events.[11][12][15]
• Can be aromatized to estradiol, which is beneficial for bone health but may contribute to gynecomastia and fluid retention in some men.[11][12][15]

What the evidence supports

Clear indications: when TRT is strongly supported

Across guidelines and major reviews, TRT is most strongly supported when:[1][8][11][13]

• The patient has documented classical hypogonadism (primary or secondary) with clear structural, genetic, or irreversible causes.
• Testosterone is repeatedly below the reference range on morning samples, measured with accurate assays.
• The man has consistent symptoms: low libido, reduced spontaneous erections, fatigue, decreased shaving frequency or body hair, low bone density, reduced muscle mass, or delayed puberty in younger men.

In these settings, evidence supports:

• Improved sexual desire and activity and modest improvements in erectile function.[1][8][11][13]
• Increased lean mass and reduced fat mass, with small to moderate gains in strength.[2][8][13]
• Increased bone mineral density, particularly at the lumbar spine and hip.[2][8][11][13]
• Better mood and sense of well‑being in many, though not all, men.[2][8][11]

Gray zone: functional or age‑related low T

For men with age‑related or functional hypogonadism, the picture is more nuanced:

• Sexual function

  • TRT consistently improves libido and sexual activity scores in trials of older men with low T.[1][10][13]
  • Benefits for erectile dysfunction are smaller and less predictable, especially when vascular disease or diabetes are primary drivers; PDE5 inhibitors often remain first‑line for ED.[1][10]

• Energy, mood, and cognition

  • Some studies show small improvements in mood, depressive symptoms, and vitality, but the effect sizes are modest and not universal.[1][10][12][14]
  • Evidence for cognitive enhancement is weak and inconsistent.[1][10][14]

• Metabolic health

  • Modest improvements in waist circumference, insulin sensitivity, and some lipid parameters have been observed, particularly in men with metabolic syndrome or type 2 diabetes.[6][8][10]
  • However, long‑term reduction in cardiovascular events or diabetes progression has not been demonstrated.[7][10][14]

• Longevity and hard outcomes

  • No high‑quality trial has shown that TRT extends lifespan, prevents myocardial infarction or stroke, or robustly prevents fractures in age‑related low T.[1][7][10][14]

Most recent reviews argue for a patient‑centric, trial‑based approach: optimize lifestyle and reversible factors first, then consider a closely monitored TRT trial for persistent, distressing symptoms plus confirmed low T after a full risk–benefit discussion.[1][10][14]

Practical takeaways

For men considering testosterone with an eye on healthspan and longevity, several principles emerge.

1. Confirm that testosterone is truly low

• Measure morning total testosterone on at least two separate days, ideally using a reliable assay.[1][8][10][11]
• Consider free testosterone when SHBG is abnormal (obesity, aging, thyroid disease, liver disease).[1][10]
• Evaluate LH, FSH, prolactin, and, when indicated, pituitary imaging to distinguish primary from secondary causes.[1][11][13]

2. Look for—and treat—reversible drivers

Before starting TRT, evidence supports systematically reviewing:[6][10][14]

• Obesity and visceral fat, with a focus on weight loss through diet and exercise.
• Sleep apnea, which independently lowers testosterone and increases cardiometabolic risk.
• Medications such as opioids, glucocorticoids, and some psychotropics that suppress the HPT axis.
• Chronic systemic illness, depression, excessive alcohol, and poorly controlled diabetes.

In some men, addressing these factors raises testosterone into the normal range without TRT.[6][10]

3. Define realistic goals

If, after full evaluation, TRT is considered, the evidence suggests framing expectations around:

• Most likely benefits: improved libido and sexual activity; modest improvements in energy, mood, and body composition.[1][2][8][10][11][13]
• Less certain benefits: erectile function, physical performance in daily life, prevention of fractures or cardiometabolic events.[1][7][10][12][14]

TRT is best viewed as a symptom‑relief and function‑supporting therapy, not a guaranteed path to extended lifespan or “optimized masculinity.”

4. Monitor closely and regularly

Guidelines and reviews converge on a monitoring framework:[9][11][12][15]

• Baseline: PSA, digital rectal exam (as appropriate), hematocrit/hemoglobin, lipids, liver function, fasting glucose or HbA1c, and cardiovascular risk assessment.
• Follow‑up: Recheck testosterone, hematocrit, and PSA at about 3–6 months, then at least annually.
• Dose adjustment: Aim for testosterone in the mid‑normal range, not supraphysiologic levels.
• Stop or modify therapy if hematocrit exceeds guideline thresholds, PSA rises significantly, or if there is a new cardiovascular event or concerning symptoms.[9][11][15]

5. Consider fertility and life stage

Because exogenous testosterone suppresses spermatogenesis, it is generally not appropriate for men trying to conceive in the near term.[11][15] Alternatives such as clomiphene citrate, hCG, or other fertility‑preserving strategies are often preferred in that scenario.

Caveats and unknowns

Despite decades of clinical use, there are still significant evidence gaps.

1. Long‑term cardiovascular safety

• Meta‑analyses and narrative reviews describe a patchwork of findings: some observational studies suggested increased major adverse cardiovascular events (MACE), others suggested neutral or even beneficial effects.[7][12][14]
• More recent evaluations emphasize that trials are often too small and too short to detect or exclude modest changes in event rates.[7][12][14][15]
• The consensus: cardiovascular risk remains uncertain, particularly in older men with existing CVD or multiple risk factors.

2. Prostate cancer risk over decades

• Short‑ and medium‑term data do not show a clear increase in prostate cancer incidence among carefully selected men on TRT.[1][8][11][13][14]
• However, men in trials are typically screened and followed more intensively than the general population, and follow‑up durations are often under 5 years—far shorter than prostate carcinogenesis timelines.

3. Use in men with borderline levels

• Many men present with borderline low testosterone and non‑specific symptoms (fatigue, low mood, mild sexual changes).
• For this group, high‑quality evidence that TRT provides meaningful, durable benefits over lifestyle optimization and targeted treatment of comorbidities is limited.[1][10][12][14]

4. Non‑medical use and supraphysiologic dosing

• Most safety and efficacy data come from men treated to physiologic levels.
• Extrapolating these findings to non‑medical use or to supraphysiologic regimens common in bodybuilding is not appropriate; risks of erythrocytosis, dyslipidemia, hepatic strain (with some oral agents), and psychiatric effects are substantially higher, but outside the scope of therapeutic TRT trials.[12][15]

5. Longevity framing

From a longevity perspective, the current evidence says:

• TRT for clear hypogonadism likely improves quality of life and may indirectly support healthier aging through preserved bone and muscle, better mood, and improved sexual health.[1][2][8][11][13]
• For age‑related low T, TRT is best viewed as a symptom‑targeted intervention with uncertain effects on lifespan or major disease outcomes, rather than a general anti‑aging hormone.[1][7][10][14]

The through‑line across guidelines and reviews is caution rather than alarmism: use testosterone where indications are solid, avoid it where risks clearly outweigh benefits, and stay humble about what we still do not know—especially when the goal shifts from symptom relief to extending healthspan and longevity.